Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company founded in 2023 and publicly launched in April 2024.

With $1 billion in seed funding, it is recognized for having the largest launch in AI-driven drug discovery. Headquartered in South San Francisco, California, and with a research presence in Seattle, Xaira focuses on re-engineering drug discovery and development through advanced generative AI. The company's mission is to transform disease treatment by turning drug discovery into an engineering discipline. Xaira develops its own drugs using a proprietary platform that combines expertise in disease biology, drug design, and AI. Its technological capabilities include molecular design for antibody and protein development, a virtual cell model for predicting outcomes, and integrated proteomics for protein analysis. Xaira primarily operates as a B2B entity, focusing on drug discovery while also exploring potential revenue-sharing models for its AI platforms.